Market News & Trends
Ocuphire Announces Enrollment of First Patients in Second Phase 3 Pivotal Trial (MIRA-3) for Nyxol in Reversal of Mydriasis
Ocuphire Pharma, Inc. recently announced the first subjects have been enrolled in the MIRA-3 Phase 3 pivotal trial evaluating Nyxol Eye Drops in the reversal…
Synlogic Presents Data Demonstrating Reductions in Plasma Phenylalanine Levels in Patients With Phenylketonuria Treated With SYNB1618
Synlogic, Inc. recently announced presentation of interim data from the company's Phase 2 SynPheny-1 clinical trial showing that treatment with the investigational Synthetic Biotic medicine SYNB1618…
Owen Mumford Announces £14-Million Investment in New, State-of-the-Art BREEAM-Certified Premises
Owen Mumford, a global leader in the design, manufacture and advancement of medical devices, today announced that work has started on the build of a…
Zealand Pharma Announces Successful Outcome of Phase 1b Clinical Trial With GLP1-GLP2 Dual Receptor Agonist
Zealand Pharma A/S recently announced topline results from its Phase 1b multiple ascending dose trial with dapiglutide. In this randomized, double-blind, placebo-controlled, multiple ascending dose…
Apollomics Doses First Patient in Phase 3 Clinical Trial With APL-106 (Uproleselan Injection) in Chinese Patients With Relapsed/Refractory Acute Myeloid Leukemia
Apollomics Inc. recently announced the first patient has been successfully dosed in a Phase 3 clinical trial of APL-106 (uproleselan injection) for the treatment of…
Dave Palmer Promoted to Operations Manager Role for Micropore Technologies
With a burgeoning global client list following recent breakthroughs in the use of its unique crossflow technology for the production of lipid nanoparticles, UK-based Micropore…
Stanford Scientists First to Identify New Cellular Correlates of Protection Against Influenza for an Oral Flu Vaccine Developed by Vaxart
A new Stanford study published in Cell Host and Microbe has demonstrated that VXA-A1.1, an investigational oral tablet flu vaccine under development by Vaxart, Inc.,…
Metrics Contract Services Completes ANVISA Regulatory Inspection
Metrics Contract Services, a division of Mayne Pharma, recently announced its Greenville, NC, facility has successfully completed an inspection by the Agência Nacional de Vigilância…
BioNTech Receives FDA Fast Track Designation for its FixVac Candidate BNT111 in Advanced Melanoma
BioNTech SE recently announced the US FDA granted Fast Track Designation for BNT111, an investigational cancer immunotherapy for the potential treatment of advanced melanoma. BNT111…
Sterling Pharma Solutions Announces $13.5-Million Investment at Dudley, UK, to Increase Process Development & Manufacturing Capacity
Sterling Pharma Solutions recently announced the next phase of a multi-year investment strategy at its site in Dudley, UK. The $13.5-million plan will see the…
EXCLUSIVE ONLINE CONTENT
Acer Therapeutics & Relief Therapeutics Announce NDA Submission for ACER-001 for Treatment of Urea Cycle Disorders
Acer Therapeutics Inc. Relief Therapeutics recently announced the submission of a New Drug Application (NDA) to the US FDA for ACER-001 (sodium phenylbutyrate) for the treatment of Urea Cycle Disorders (UCDs)….